Atr-101 (DrugBank: -)
2 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 75 | Cushing disease | 2 |
| 81 | Congenital adrenal hyperplasia | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-002240-17-GB (EUCTR) | 16/05/2017 | 06/03/2017 | A Study of ATR-101 for the Treatment of Cushing’s Syndrome | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome | endogenous Cushing’s syndrome MedDRA version: 20.0;Level: SOC;Classification code 10014698;Term: Endocrine disorders;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Millendo Therapeutics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 16 | Phase 2 | United States;United Kingdom | |||
| 2 | NCT03053271 (ClinicalTrials.gov) | April 13, 2017 | 6/2/2017 | A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome | Cushing Syndrome | Drug: ATR-101;Drug: Placebo | Millendo Therapeutics US, Inc. | NULL | Terminated | 18 Years | 80 Years | All | 4 | Phase 2 | United States;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-004878-34-FR (EUCTR) | 18/09/2018 | 24/04/2018 | A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia | A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia | Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: Nevanimibe Hydrochloride Product Code: ATR-101 INN or Proposed INN: Nevanimibe hydrochloride Other descriptive name: CI-984, 17AA70, PD 132301-2 | Millendo Therapeutics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | France;Spain;Brazil;Israel | ||
| 2 | EUCTR2017-004878-34-ES (EUCTR) | 01/08/2018 | 21/05/2018 | A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia | A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia | Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: Nevanimibe Hydrochloride Product Code: ATR-101 INN or Proposed INN: Nevanimibe hydrochloride Other descriptive name: CI-984, 17AA70, PD 132301-2 | Millendo Therapeutics US, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | France;Brazil;Spain;Israel | ||
| 3 | NCT02804178 (ClinicalTrials.gov) | May 18, 2016 | 1/6/2016 | A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia | A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia | Drug: ATR-101 | Millendo Therapeutics, Inc. | NULL | Completed | 18 Years | 80 Years | All | 10 | Phase 2 | United States |